Sandro Santagata

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi request reprint Intramedullary neuroma of the cervicomedullary junction. Case report
    Sandro Santagata
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02130, USA
    J Neurosurg Spine 5:362-6. 2006
  2. pmc BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications
    Dora Dias-Santagata
    Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 6:e17948. 2011
  3. pmc Tight coordination of protein translation and HSF1 activation supports the anabolic malignant state
    Sandro Santagata
    Department of Pathology, Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02215, USA
    Science 341:1238303. 2013
  4. pmc Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1
    Lori A Ramkissoon
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 110:8188-93. 2013
  5. pmc CRX is a diagnostic marker of retinal and pineal lineage tumors
    Sandro Santagata
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts, United States of America
    PLoS ONE 4:e7932. 2009
  6. pmc Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas
    Priscilla K Brastianos
    1 Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA 2 Division of Neuro Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA 3 Harvard Medical School, Boston, Massachusetts, USA 4 Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA 5 Broad Institute of MIT and Harvard, Boston, Massachusetts, USA 6
    Nat Genet 46:161-5. 2014
  7. pmc DNA fragmentation simulation method (FSM) and fragment size matching improve aCGH performance of FFPE tissues
    Justin M Craig
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, United States of America
    PLoS ONE 7:e38881. 2012
  8. pmc Using the heat-shock response to discover anticancer compounds that target protein homeostasis
    Sandro Santagata
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, United States
    ACS Chem Biol 7:340-9. 2012
  9. pmc Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas
    Yongji Tian
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    J Mol Diagn 13:669-77. 2011
  10. pmc Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells
    Mikko Taipale
    Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, USA
    Nat Biotechnol 31:630-7. 2013

Detail Information

Publications20

  1. ncbi request reprint Intramedullary neuroma of the cervicomedullary junction. Case report
    Sandro Santagata
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02130, USA
    J Neurosurg Spine 5:362-6. 2006
    ..This case may represent the first true traumatic intramedullary neuroma of the CMJ diagnosed in a living patient and treated surgically...
  2. pmc BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications
    Dora Dias-Santagata
    Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 6:e17948. 2011
    ..1%) giant cell GBM (gcGBM). The finding that BRAF V600E mutations are common in the majority of PXA has important therapeutic implications and may help in differentiating less aggressive PXAs from lethal gcGBMs and GBMs...
  3. pmc Tight coordination of protein translation and HSF1 activation supports the anabolic malignant state
    Sandro Santagata
    Department of Pathology, Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02215, USA
    Science 341:1238303. 2013
    ....
  4. pmc Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1
    Lori A Ramkissoon
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 110:8188-93. 2013
    ..Our results define clinically relevant molecular subclasses of diffuse PLGGs and highlight a potential role for the MYB family in the biology of low-grade gliomas...
  5. pmc CRX is a diagnostic marker of retinal and pineal lineage tumors
    Sandro Santagata
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts, United States of America
    PLoS ONE 4:e7932. 2009
    ..To determine the biologic and diagnostic potential of CRX in human tumors of the retina and pineal, we examined its expression in multiple settings...
  6. pmc Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas
    Priscilla K Brastianos
    1 Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA 2 Division of Neuro Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA 3 Harvard Medical School, Boston, Massachusetts, USA 4 Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA 5 Broad Institute of MIT and Harvard, Boston, Massachusetts, USA 6
    Nat Genet 46:161-5. 2014
    ..Adamantinomatous and papillary craniopharyngiomas harbor mutations that are mutually exclusive and clonal. These findings have important implications for the diagnosis and treatment of these neoplasms. ..
  7. pmc DNA fragmentation simulation method (FSM) and fragment size matching improve aCGH performance of FFPE tissues
    Justin M Craig
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, United States of America
    PLoS ONE 7:e38881. 2012
    ..This study demonstrates that rigorous control of DNA fragment size improves aCGH performance. This methodological advance will permit the routine analysis of FFPE tumor samples for clinical trials and in daily clinical practice...
  8. pmc Using the heat-shock response to discover anticancer compounds that target protein homeostasis
    Sandro Santagata
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, United States
    ACS Chem Biol 7:340-9. 2012
    ..From a chemical biology perspective, they define a robust approach for discovering candidate compounds that target the malignant phenotype by disrupting protein homeostasis...
  9. pmc Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas
    Yongji Tian
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    J Mol Diagn 13:669-77. 2011
    ..These results show that fusion transcripts and mutations can be detected reliably in standard FFPE specimens and may be useful for incorporation into future studies of pediatric gliomas in basic science or clinical trials...
  10. pmc Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells
    Mikko Taipale
    Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, USA
    Nat Biotechnol 31:630-7. 2013
    ....
  11. pmc Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations
    Priscilla K Brastianos
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Nat Genet 45:285-9. 2013
    ..These mutations were present in therapeutically challenging tumors of the skull base and higher grade. These results begin to define the spectrum of genetic alterations in meningiomas and identify potential therapeutic targets...
  12. pmc Multiplex amplification coupled with COLD-PCR and high resolution melting enables identification of low-abundance mutations in cancer samples with low DNA content
    Coren A Milbury
    Department of Radiation Oncology, Dana Farber Brigham and Women s Cancer Center, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Mol Diagn 13:220-32. 2011
    ..In summary, we demonstrate an efficient approach to increase screening capabilities from limited DNA material via multiplex-PCR and improve mutation detection sensitivity via COLD-PCR amplification...
  13. pmc Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome
    Yoon Jae Cho
    Children s Hospital Boston, Boston, MA 02115, USA
    J Clin Oncol 29:1424-30. 2011
    ....
  14. pmc Profiling critical cancer gene mutations in clinical tumor samples
    Laura E MacConaill
    Center for Cancer Genome Discovery, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA
    PLoS ONE 4:e7887. 2009
    ..We report the implementation of a genotyping and validation algorithm that enables robust tumor mutation profiling in the clinical setting...
  15. doi request reprint Phase II study of protracted daily temozolomide for low-grade gliomas in adults
    Santosh Kesari
    Dana Farber Brigham and Women s Cancer Center, Center for Neuro Oncology, Boston, MA 02115, USA
    Clin Cancer Res 15:330-7. 2009
    ..Protracted treatment with temozolomide potentially overcomes MGMT resistance and improves outcome. We conducted a phase II study of protracted daily temozolomide in adults with low-grade gliomas...
  16. pmc Mass spectrometry imaging as a tool for surgical decision-making
    David Calligaris
    Department of Neurosurgery, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, 02115, USA
    J Mass Spectrom 48:1178-87. 2013
    ....
  17. pmc The master regulator of the cellular stress response (HSF1) is critical for orthopoxvirus infection
    Claire Marie Filone
    Department of Microbiology, Boston University School of Medicine, Boston, Massachusetts, United States of America United States Army Medical Research Institute of Infectious Diseases, Virology Division, Fort Detrick, Maryland, United States of America
    PLoS Pathog 10:e1003904. 2014
    ..The dependence on HSF1 and its chaperone network offers multiple opportunities for antiviral drug development. ..
  18. pmc High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer
    Sandro Santagata
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 108:18378-83. 2011
    ..The findings indicate that HSF1 should be evaluated prospectively as an independent prognostic indicator in ER-positive breast cancer. HSF1 may ultimately be a useful therapeutic target in cancer...
  19. ncbi request reprint Embryonic stem cell transcription factor signatures in the diagnosis of primary and metastatic germ cell tumors
    Sandro Santagata
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Am J Surg Pathol 31:836-45. 2007
    ....
  20. ncbi request reprint Anaplastic variant of medulloblastoma mimicking a vestibular schwannoma
    Sandro Santagata
    Division of Neuropathology, Department of Pathology, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    J Neurooncol 81:49-51. 2007